myriocin

Overview

Myriocin is a serine palmitoyltransferase inhibitor used as a pharmacological probe of the TORC2 signaling pathway in yeast models. It is not a clinical therapeutic agent but is used in mechanistic studies to assess TORC2 pathway activation status.

Evidence in the corpus

• All four viable RHOA hotspot mutants (R5Q, G17V, C16R, A161P) expressed in a humanized yeast model conferred increased myriocin resistance (250–1000 ng/mL) relative to controls, indicating TORC2 pathway activation as a shared downstream node across oncogenic RHOA variants regardless of GOF vs LOF classification PMID:24816253.

Resistance mechanisms

Cancer types (linked)

Sources

This page was processed by entity-page-writer on 2026-05-11.